Why Shares of AC Immune Jumped This Week
The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences...
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Three clinical readouts delivered year to date; four more expected by year-endFirst patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE...
AC Immune Holds Annual General Meeting of Shareholders
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...